Literature DB >> 28363871

Impact of antibody subclass and disulfide isoform differences on the biological activity of CD200R and βklotho agonist antibodies.

Ognjen Grujic1, Jennitte Stevens2, Robert Y-T Chou2, Jennifer V Weiszmann3, Laura Sekirov1, Christy Thomson1, Anita Badh1, Stephanie Grauer1, Brian Chan1, Kevin Graham2, Kathy Manchulenko1, Thomas M Dillon2, Yang Li3, Ian N Foltz4.   

Abstract

Agonism of cell surface receptors by monoclonal antibodies is dependent not only on its ability to bind the target, but also to deliver a biological signal through receptors to the cell. Immunoglobulin G2 antibodies (IgG2s) are made up of a mixture of distinct isoforms (IgG2-A, -B and A/B), which differ by the disulfide connectivity at the hinge region. When evaluating panels of agonistic antibodies against CD200 receptor (CD200R) or βklotho receptor (βklotho), we noticed striking activity differences of IgG1 or IgG2 antibodies with the same variable domains. For the CD200R antibody, the IgG2 antibody demonstrated higher activity than the IgG1 or IgG4 antibody. More significantly, for βklotho, agonist antibodies with higher biological activity as either IgG2 or IgG1 were identified. In both cases, ion exchange chromatography was able to isolate the bioactivity to the IgG2-B isoform from the IgG2 parental mixture. The subclass-related increase in agonist activity was not correlated with antibody aggregation or binding affinity, but was driven by enhanced avidity for the CD200R antibody. These results add to the growing body of evidence that show that conformational differences in the antibody hinge region can have a dramatic impact on the antibody activity and must be considered when screening and engineering therapeutic antibody candidates. The results also demonstrate that the IgG1 (IgG2-A like) or the IgG2-B form may provide the most active form of agonist antibodies for different antibodies and targets.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Agonist; Antibody isoform; CD200R; Subclass; βklotho

Mesh:

Substances:

Year:  2017        PMID: 28363871     DOI: 10.1016/j.bbrc.2017.03.145

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

Review 1.  Agonist antibody discovery: Experimental, computational, and rational engineering approaches.

Authors:  John S Schardt; Harkamal S Jhajj; Ryen L O'Meara; Timon S Lwo; Matthew D Smith; Peter M Tessier
Journal:  Drug Discov Today       Date:  2021-09-24       Impact factor: 7.851

Review 2.  Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases.

Authors:  Yujia Zhai; Reza Moosavi; Mingnan Chen
Journal:  Front Immunol       Date:  2021-04-21       Impact factor: 7.561

3.  A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity.

Authors:  Sally Yu Shi; Ya-Wen Lu; Zhi Liu; Jennitte Stevens; Christopher M Murawsky; Vicki Wilson; Zhonghua Hu; William G Richards; Mark Leo Michaels; Jun Zhang; Wei Yan; Yang Li
Journal:  J Biol Chem       Date:  2018-02-26       Impact factor: 5.157

Review 4.  Immune Checkpoints as Therapeutic Targets in Autoimmunity.

Authors:  Christopher Paluch; Ana Mafalda Santos; Consuelo Anzilotti; Richard J Cornall; Simon J Davis
Journal:  Front Immunol       Date:  2018-10-08       Impact factor: 7.561

5.  Rapid, automated characterization of disulfide bond scrambling and IgG2 isoform determination.

Authors:  Anja Resemann; Lily Liu-Shin; Guillaume Tremintin; Arun Malhotra; Adam Fung; Fang Wang; Gayathri Ratnaswamy; Detlev Suckau
Journal:  MAbs       Date:  2018-10-02       Impact factor: 5.857

6.  R409K mutation prevents acid-induced aggregation of human IgG4.

Authors:  Hiroshi Namisaki; Seiji Saito; Keiko Hiraishi; Tomoko Haba; Yoshitaka Tanaka; Hideaki Yoshida; Shigeru Iida; Nobuaki Takahashi
Journal:  PLoS One       Date:  2020-03-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.